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To determine whether the insulin dose-response curves
for suppression of endogenous glucose production
(EGP) and stimulation of splanchnic glucose uptake
(SGU) differ in nondiabetic humans and are abnormal in
type 2 diabetes, 14 nondiabetic and 12 diabetic subjects
were studied. Glucose was clamped at 9.5 mmol/l and
endogenous hormone secretion inhibited by somatosta-
tin, while glucagon and growth hormone were replaced
by an exogenous infusion. Insulin was progressively
increased from 150 to 350 and 700 pmol/l by means
of an exogenous insulin infusion, while EGP, SGU, and
leg glucose uptake (LGU) were measured using the
splanchnic and leg catheterization methods, combined
with a [3-3H]glucose infusion. In nondiabetic subjects,
an increase in insulin from 150 to 350 pmol/l re-
sulted in maximal suppression of EGP, whereas SGU
continued to increase (P < 0.001) when insulin was
increased to 700 pmol/l. In contrast, EGP progres-
sively decreased (P < 0.001) and SGU progressively
increased (P < 0.001) in the diabetic subjects as insulin
increased from 150 to 700 pmol/l. Although EGP was
higher (P < 0.01) in the diabetic than nondiabetic
subjects only at the lowest insulin concentration, SGU
was lower (P < 0.01) in the diabetic subjects at all
insulin concentrations tested. On the other hand, in
contrast to LGU and overall glucose disposal, the incre-
ment in SGU in response to both increments in insulin
did not differ in the diabetic and nondiabetic subjects,
implying a right shifted but parallel dose-response
curve. These data indicate that the dose-response
curves for suppression of glucose production and stim-
ulation of glucose uptake differ in nondiabetic subjects
and are abnormal in people with type 2 diabetes. Taken
together, these data also suggest that agents that en-
hance SGU in diabetic patients (e.g. glucokinase activa-
tors) are likely to improve glucose tolerance. Diabetes
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ype 2 diabetes is associated with hepatic and
extrahepatic insulin resistance (1–5). Hepatic
insulin resistance is characterized by both exces-
sive hepatic glucose production and decreased
hepatic glucose uptake (2,3,6–15). Impaired suppression
of glucose production is most evident at low insulin
concentrations (less than 300 pmol/l), with normal sup-
pression eventually being observed at insulin concentra-
tions (600 pmol/l) that are commonly observed in the
portal vein of nondiabetic individuals (1–3,6,13–15). How-
ever, the insulin dose-response curve for stimulation of
hepatic glucose uptake has not been as extensively stud-
ied. It also is not known whether defects in hepatic
glucose uptake evident in people with type 2 diabetes at
low insulin concentrations (6,7) resolve at high insulin
concentrations. If so, this would imply that the origin of
the defect (e.g. decreased glucokinase activity) is relative
rather than absolute.
In one of the earliest studies examining the effects of
insulin on splanchnic glucose uptake, Ferrannini et al. (8)
reported that neither splanchnic glucose uptake (SGU) nor
splanchnic (tracer) glucose extraction increased in nondi-
abetic volunteers when plasma insulin concentrations
were increased from 330 to 1,200 pmol/l. However, the
number of subjects studied at high insulin concentrations
was small (n  2). In subsequent experiments, DeFronzo
et al. (16) reported that SGU in nondiabetic subjects
remained unchanged when insulin was increased from
220 to 7,200 pmol/l. The effects of insulin also may not
have been detected in those experiments (16) because
glucose was clamped at euglycemic levels, thereby limit-
ing hepatic glucose uptake and, with the exception of the
600 pmol/l group (n  6), the number of subjects studied
at the other insulin concentration (n  2–4) was also
small. In contrast, Meyers et al. (17) reported that both
hepatic glucose uptake and fractional hepatic glucose
extraction increased in nondiabetic dogs as insulin in-
creased from 200 to 1,200 pmol/l. In addition, Petersen
et al. (18) demonstrated that in the presence of hypergly-
cemia and glucagon deficiency, glycogen synthesis from
extracellular glucose (and therefore presumably hepatic
glucose uptake) increased in nondiabetic subjects when
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insulin concentrations were increased from 40 to 400
pmol/l, implying a concurrent increase in hepatic glucose
uptake. More recently, we observed (6) that SGU, while
lower in type 2 diabetic than nondiabetic subjects, in-
creased in both groups when insulin was increased from
70 to 140 pmol/l. On the other hand, in a separate
series of experiments (7) performed at higher insulin
concentrations (300 pmol/l), the difference in SGU be-
tween the diabetic and nondiabetic subjects appeared to
narrow, suggesting that the dose-response relationship
differed in the two groups. However, comparison of rates
of SGU in those studies is difficult because the route of
glucose delivery (intravenous versus intraduodenal) and
the insulin concentrations differed.
There are theoretical reasons why the shape of the
dose-response curves for insulin-induced suppression of
glucose production and stimulation of SGU may not be the
same and may differ in diabetic and nondiabetic individu-
als. Insulin decreases glucose production by both direct
and indirect mechanisms (19,20). Low insulin concentra-
tions inhibit glycogenolysis, whereas higher insulin con-
centrations are required to decrease gluconeogenesis
(11,21–23). The resultant decrease in intrahepatic glucose-
6-phosphate concentrations and possibly glucose-6-phos-
phatase activity results in a decrease in hepatic glucose
release (18,24). In contrast, in the absence of hyperglyce-
mia, insulin has only a minimal effect on hepatic glucose
uptake (18). However, in the presence of hyperglycemia,
insulin can increase hepatic glucose uptake, at least in part
by increasing glucokinase activity, intrahepatic glucose-6-
phosphate concentrations, and hepatic glycogen syn-
thetase activity (18,24,25). Diabetes has been shown to be
associated with defects in essentially all of the processes
that regulate hepatic glucose uptake and hepatic glucose
production (10,25–29). It therefore would not be surprising
if the insulin dose-response curves for the suppression of
glucose production and stimulation of SGU differed in
nondiabetic humans and were abnormal in people with
type 2 diabetes.
The present experiments sought to address these ques-
tions by using the hepatic catheterization technique in
combination with the tracer dilution method to concur-
rently measure glucose production and SGU in both
diabetic and nondiabetic subjects. Glucose concentrations
were clamped at 9.5 mmol/l in both diabetic and nondi-
abetic subjects, while insulin concentrations were in-
creased from 150 to 700 pmol/l to concurrently
stimulate hepatic and muscle glucose uptake. Endogenous
hormone secretion was inhibited with somatostatin, and
glucagon was replaced to ensure that portal insulin and
glucagon concentrations were the same in both groups.
We report that although the shapes of the dose-response
curves differ, insulin concentrations spanning the physio-
logic range inhibit endogenous glucose production (EGP)
and stimulate SGU in both diabetic and nondiabetic hu-
mans. However, although increases in insulin concentra-
tions resulted in a progressive increase in SGU in both
groups, rates remained lower in the diabetic than nondia-
betic subjects at all insulin concentrations tested. These
data indicate that defects in the ability of insulin to
stimulate hepatic glucose uptake likely contribute to hy-
perglycemia in people with type 2 diabetes. They also add
further support to the concept that the mechanisms by
which insulin regulates hepatic glucose uptake and pro-
duction differ in diabetic and nondiabetic humans.
RESEARCH DESIGN AND METHODS
After approval from the Mayo Institutional Review Board, 14 nondiabetic
subjects and 12 subjects with type 2 diabetes gave informed written consent
to participate in the study. All subjects were in good health and at a stable
weight. None regularly engaged in vigorous physical exercise. None of the
parents, siblings, and children (first-degree relatives) of the nondiabetic
subjects had a history of diabetes. At the time of screening, two of the diabetic
subjects were being treated with lifestyle modifications alone and seven with
either a sulfonylurea or metformin. One subject was on insulin alone, and two
were on both insulin and metformin. Oral hypoglycemic agents were discon-
tinued 3 weeks prior to study and long-acting insulin switched to regular
insulin with meals, beginning with the midday meal 2 days prior to study.
Subjects were on no medications at the time of the study other than either
thyroxine or hormone replacement therapy. All subjects were instructed to
follow a weight maintenance diet containing 55% carbohydrate, 30% fat, and
15% protein for at least 3 days prior to the day of study. Diabetic and
nondiabetic subjects, respectively, were matched for age (65  1 vs. 63  2
years), sex (6/6 vs. 7/7 men/women), total body weight (89  4.0 vs. 86  3.3
kg), BMI (32.1  1.2 vs. 30.1  1.3 kg/m2), and body fat (39.1  3.0 vs. 34.2 
2.5%). Fasting plasma glucose (8.0  0.3 vs. 5.3  0.1 mmol/l) and HbA1c (9.1 
1.0 vs. 5.2  1.0%), measured at the time of screening, were significantly (P 
0.001) higher in diabetic versus nondiabetic subjects.
Subjects were admitted to the Mayo Clinic General Clinical Research
Center at 1700 on the evening before the study. A standard 10-cal/kg meal (55%
carbohydrate, 30% fat, and 15% protein) was eaten between 1730 and 1800.
After the meal, an 18-gauge catheter was inserted into a forearm vein and an
infusion of insulin (100 units regular human insulin in 1 l of 0.9% saline
containing 5 ml of 25% human albumin) was started in the diabetic subjects or
saline in the nondiabetic subjects. The insulin infusion rate was adjusted to
maintain glucose concentrations in the diabetic subjects at 5 mmol/l during
the night (30). In addition, 0.9% saline along with 20 mEq of KCl per l was
infused at 60 ml/min throughout the night in the diabetic subjects and during
the insulin clamp in both the nondiabetic and diabetic subjects.
At 0600 on the morning after admission, a urinary bladder catheter was
placed, after which the subjects were taken to an interventional radiology
suite where femoral artery, femoral venous, and hepatic venous catheters
were placed as previously described (6,7). The arterial catheter was used for
blood sampling, and the arterial sheath was used for indocyanine green
infusion (Akorn, Buffalo Grove, IL). The venous catheters were used for blood
sampling. Although, the experimental design is similar to that previously
reported by us (6,7), none of the subjects in the present experiments
participated in those studies.
Subjects were then returned to the General Clinical Research Center,
where at 0900, a primed-continuous infusion of [3-3H] glucose (12 Ci
primed, 0.12 Ci/min continuous; New England Nuclear, Boston, MA) into a
forearm vein was started. Infusions of somatostatin (60 ng  kg1  min1),
growth hormone (3 ng  kg1  min1), and glucagon (0.65 ng  kg1  min1)
were also started (t  0 min) and continued until the end of the study. Insulin
was infused at a rate of 0.78 mU  kg lean body wt1  min1 (0.5 mU  kg total
body wt1  min1) from 0 to 180 min, 1.56 (1.0) from 181 to 300 min, and 3.1
(2.0) from 301 to 420 min. A dextrose infusion also was begun and the rate
adjusted so as to maintain plasma glucose concentrations at 9.3 mmol/l
(165 mg/dl) over the next 7 h of study. All infused glucose contained [3-3H]
glucose to minimize the change in plasma glucose specific activity (31,32). In
addition, the rate of the “basal” [3-3H] glucose infusion also was reduced to
mimic the anticipated changes in EGP (33).
Analytical techniques. All samples were placed in ice, centrifuged at 4°C,
and separated. Plasma indocyanine green concentration was measured spec-
trophotometrically at 805 nm on the day of study as previously described (34).
All other samples were stored at 20°C until analysis. Plasma glucose was
measured by a glucose oxidase method using a YSI glucose analyzer (Yellow
Springs, OH). Plasma insulin was measured using a chemiluminescence
method with the Access Ultrasensitive Immunoenzymatic assay system (Beck-
man, Chaska, MN). C-peptide and glucagon concentrations were assayed by
radioimmunoassay (RIA; Linco Research, St. Louis, MO). Growth hormone
was measured with the Access hGH two-site immunoenzymatic assay (Beck-
man). Body composition, including percentage of fat and lean body mass,
were measured using dual-energy X-ray absorptiometry (DPX-IQ scanner,
SmartScan version 4.6; Hologic, Waltham, MA).
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Calculations. Splanchnic plasma flow was calculated by dividing the indo-
cyanine green infusion rate by the arterial-hepatic venous concentration
gradient of the dye, and leg plasma flow was calculated by dividing the dye
infusion rate by the concentration gradient across the leg (34,35). The
corresponding blood flows were calculated by dividing the respective plasma
flow by (1  hematocrit). Blood glucose concentrations were calculated by
multiplying the plasma glucose concentrations by 0.85. Net splanchnic glucose
balance was calculated as the product of the arterial-hepatic vein glucose
difference and the median of quadruple determinations of splanchnic blood
flow. The splanchnic-to-glucose extraction ratio was calculated as the differ-
ence of arterial and hepatic venous [3-3H] glucose concentrations divided by
the arterial [3-3H] glucose concentration. SGU was determined by multiplying
the arterial glucose concentration by splanchnic-to-glucose extraction ratio
and splanchnic blood flow. Leg glucose uptake (LGU) was calculated as the
difference between the femoral arterial and the femoral venous glucose
concentration times the median of quadruple determinations of leg blood
flow. The leg-to-glucose extraction ratio was calculated as the difference in
arterial and femoral venous [3-3H] glucose concentration divided by the
arterial [3-3H] glucose concentration. Rates of glucose appearance (Ra) and
disappearance (Rd) were calculated using the steady-state equations of Steele
et al. (36). EGP was determined by subtracting the glucose infusion rate from
the tracer-determined rate of glucose appearance.
Statistical analysis. Data in the text and figures are expressed as mean 
SE. All rates (including SGU and LGU) are expressed as micromoles per
kilogram of lean body mass per minute. Responses during the three dose
insulin infusions were determined by meaning the results present, respec-
tively, from 150 to 180 min, 270 to 300 min, and 390 to 420 min. Student’s
unpaired t test was used to compare results between groups (e.g. diabetic
versus nondiabetic subjects), and ANOVA was used to compare results within
a group (e.g. low- versus mid- versus high-dose insulin infusion), followed by
Student’s paired t test wherever appropriate. P  0.05 was considered
statistically significant.
RESULTS
Plasma glucose, insulin, C-peptide, and glucagon con-
centrations. Plasma glucose concentrations were higher
(P  0.001) in the diabetic than in the nondiabetic subjects
(Fig. 1A) prior to the clamp (8.0  0.3 vs. 5.5  0.1 mmol),
but did not differ during the clamp (9.3  0.1 vs. 9.3  0.1
mmol/l). Plasma insulin concentrations were slightly but
not significantly higher in the diabetic than in the nondia-
betic subjects prior to the clamp (48  6 vs. 39  5 pmol/l)
and did not differ during either the low (161  8 vs. 158 
10 pmol/l)-, middle (358  31 vs. 326  20)-, or high (727 
37 vs. 711  46)-dose insulin infusions (Fig. 1B). Plasma
C-peptide concentrations were slightly but not signifi-
cantly lower in the diabetic than in the nondiabetic sub-
jects prior to the clamp (0.42  0.05 vs. 0.52  0.04) and
were comparably suppressed to almost undetectable lev-
els in both groups (Fig. 1C). Plasma glucagon concentra-
tions (Fig. 1D) did not differ in the diabetic subjects
compared with the nondiabetic subjects either prior to
(137  9 vs. 128  5 pg/ml) or during the clamp (118  5
vs. 117  3). Plasma growth hormone concentrations also
FIG. 1. Plasma glucose (A), insulin (B), C-peptide
(C), and glucagon (D) concentrations observed in the
diabetic and nondiabetic subjects prior to and during
a hyperglycemic clamp. The insulin, somatostatin,
glucagon, and growth hormone infusions started at
time 0.
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did not differ in the diabetic and nondiabetic groups either
prior to or during the clamps (data not shown).
Glucose infusion rates required to maintain target
glucose concentrations and [3-3H] glucose specific
activity. The glucose infusion rate required to maintain
plasma glucose at target concentrations was lower (P 
0.002) in the diabetic than nondiabetic subjects during the
low (9  2 vs. 31  5 mol  kg1  min1)-, middle (25 
4 vs. 77  7)-, and high (66  11 vs. 110  7)-dose insulin
infusions, documenting the presence of insulin resistance
(Fig. 2A). All exogenous glucose contained [3-3H] glucose
in an effort to minimize change in glucose specific activity
during the clamp. This caused plasma glucose specific
activity to reach a plateau within 60 min, enabling accurate
measurement of glucose production and disappearance
thereafter (Fig. 2B).
Net splanchnic glucose balance. Splanchnic blood flow
did not differ in the diabetic and nondiabetic subjects
during the low (1,157  79 vs. 1,524  288 ml/min)-, middle
(1,205  79 vs. 1,553  271)-, or high (1,235  65 vs.
1,687  337)-dose insulin infusions. Despite hyperglyce-
mia, net splanchnic glucose balance was negative (net
release) in the diabetic subjects during the lowest-dose
insulin infusion, becoming positive (net uptake) during the
middle-dose insulin infusion (Fig. 3). On the other hand,
net splanchnic glucose balance was positive in the nondi-
abetic subjects at all three insulin infusion rates. Net
splanchnic glucose balance increased (P  0.001, ANOVA)
with increasing insulin concentrations in both groups.
However, net splanchnic glucose balance remained lower
(P  0.05) in the diabetic than in the nondiabetic subjects
during the low (3.5  1.4 vs. 2.6  1.5 mol  kg1 
min1)-, middle (2.6  1.0 vs. 7.8  1.2)-, and high (7.1 
1.2 vs. 11.6  1.5)-dose insulin infusions.
Splanchnic glucose (tracer) extraction and uptake.
Splanchnic (tracer) glucose extraction increased (P 
0.001, ANOVA) with increasing insulin concentrations in
both groups. However, splanchnic glucose extraction re-
mained lower (P  0.02) in the diabetic than in the
nondiabetic subjects during the low (2.0  0.5 vs. 4.1 
0.5%)-, middle (3.2  0.4 vs. 5.2  0.4)-, and high (4.3  0.5
vs. 7.2  0.5)-dose insulin infusions.
The pattern of change in SGU paralleled that of splanch-
nic glucose extraction. SGU (Fig. 4A) increased (P 
0.001, ANOVA) with increasing insulin concentrations in
both the diabetic and nondiabetic subjects. On the other
FIG. 2. Glucose infusion rates (A)
required to maintain target glu-
cose concentrations and plasma
[3-3H]glucose specific activity (B)
observed in the diabetic and nondi-
abetic subjects prior to and during
a hyperglycemic clamp. The insulin,
somatostatin, glucagon, and growth
hormone infusions started at time 0.
FIG. 3. Net splanchnic glucose balance observed in the diabetic and
nondiabetic subjects during the final 30 min of the low (150 pmol/l)-,
middle (350 pmol/l)-, and high (700 pmol/l)-dose insulin infusions.
*P < 0.05 versus nondiabetic values.
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hand, SGU was lower (P  0.01) in the diabetic than
nondiabetic subjects during the low (3.3  0.9 vs. 8.5  1.3
mol  kg1  min1)-, middle (5.6  0.9 vs. 11.2  0.8)-,
and high (9.2  0.9 vs. 14.9  1.2)-dose insulin infusions.
Of note, the increment in SGU observed when the insulin
was increased from the low- to middle-dose (2.3  1.2 vs.
2.6  1.2 mol  kg1  min1) insulin infusions, and the
middle- to high-dose (3.6  1.1 vs. 4.2  1.1) insulin infu-
sions did not differ in the diabetic and nondiabetic subjects.
Leg glucose (tracer) extraction and uptake. Leg blood
flow did not differ in the diabetic and nondiabetic subjects
during the low (514  40 vs. 483  53 ml/min)-, middle
(457  30 vs. 511  45)-, or high (551  49 vs. 630 
60)-dose insulin infusions. Leg (tracer) glucose extraction
increased (P  0.001, ANOVA) with increasing insulin
concentrations in both groups. However, leg glucose ex-
traction remained lower (P  0.001) in the diabetic than in
the nondiabetic subjects during the low (1.7  0.0 vs. 7.1 
2.0%)-, middle (6.0  1.5 vs. 17.1 2.4)-, and high (15.0 
2.0 vs. 20.6  2.0)-dose insulin infusions.
The pattern of change in LGU also paralleled that of leg
glucose extraction. LGU (Fig. 4B) increased (P  0.001,
ANOVA) with increasing insulin concentrations in both the
diabetic and nondiabetic subjects. On the other hand, LGU
was lower (P  0.001) in the diabetic than in the nondia-
betic subjects during the low (1.2  0.3 vs. 4.4  1.0 mol
 kg1  min1)-, middle (3.3  0.7 vs. 14.1  2.0)-, and high
(11.2  2.5 vs. 21.4  2.0)-dose infusions. Although the
increment in LGU observed when insulin was increased
from the low to middle infusion rate (2.1  0.6 vs. 9.7  1.5
mol  kg1  min1) was lower (P  0.001) in the diabetic
than in the nondiabetic subjects, it did not differ when
insulin was increased from the middle to high infusion rate
(7.9  1.9 vs. 7.3  0.7).
Glucose disappearance and EGP. Total glucose disap-
pearance increased (P  0.001, ANOVA) with increasing
insulin concentrations in both the diabetic and non-
diabetic subjects (Fig. 5A). Glucose disappearance was
lower (P  0.01) in the diabetic than nondiabetic subjects
during the low (19  2 vs. 37  4 mol  kg1  min1)-,
middle (31  4 vs. 80  7)-, and high (71  11 vs. 114 
8)-dose insulin infusions. As with LGU, the increment in
total body glucose disappearance observed when the
insulin was increased from the low to middle infusion rate
was lower (P  0.001) in the diabetic than nondiabetic
subjects (11.9  3.1 vs. 43.1  5.1), but did not differ when
insulin was increased from the middle to high infusion rate
(40.3  8.0 vs. 33.3  4.2).
EGP in the diabetic subjects progressively decreased
(P  0.001, ANOVA) with increasing insulin concentra-
tions (Fig. 5B). On the other hand, EGP in the nondiabetic
subjects decreased (P  0.02) when insulin was increased
from the low to middle insulin infusion rates but did not
decrease thereafter. This resulted in EGP rates that were
higher (P  0.01) in the diabetic than nondiabetic subjects
FIG. 4. SGU (A) and LGU (B) observed in the diabetic and nondiabetic
subjects during the final 30 min of the low (150 pmol/l)-, middle
(350 pmol/l)-, and high (700 pmol/l)-dose insulin infusions. *P <
0.01 versus nondiabetic values.
FIG. 5. Rates of glucose disappearance (A) and EGP observed in the
diabetic and nondiabetic subjects during the final 30 min of the low
(150 pmol/l)-, middle (350 pmol/l)-, and high (700 pmol/l)-dose
insulin infusions. *P < 0.01 versus nondiabetic values.
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during the low but not the middle or high insulin infusion
rates.
Effects of duration of hyperinsulinemia on splanch-
nic glucose (tracer) extraction and uptake. In order to
determine whether SGU increased with increasing dura-
tion of hyperinsulinemia, insulin was infused at a rate of
0.78 mU  kg lean body wt1  min1 in four nondiabetic
subjects while glucose was clamped at 9.5 mmol/l for
7 h. As shown in Table 1, glucose, insulin, C-peptide, and
glucagon concentrations reached a plateau within 1 h and
did not change thereafter. The glucose infusion rate in-
creased gradually for the first 5 h, then decreased slightly
during the succeeding 2 h. Plasma [3-3H] glucose specific
activity achieved a steady state within 1 h.
Splanchnic blood flow did not differ when measured
from 150 to 180 min (1,066  96 ml/min), 270 to 300 min
(1,034  95), or 390 to 420 min (1,197  126). Splanchnic
(tracer) glucose extraction (7.9  0.4 vs. 7.6  0.8 vs. 6.9 
0.1%, respectively) and SGU (12.3  2.0 vs. 12.9  2.1 vs.
12.6  3.1 mol  kg1  min1, respectively) measured
over the same intervals also did not differ (Fig. 6).
DISCUSSION
The present studies indicate that in the presence of
hyperglycemia, an increase in insulin from 150 to 700
mol/l resulted in a progressive increase in SGU in both
diabetic and nondiabetic humans. On the other hand, EGP
was maximally suppressed in the nondiabetic subjects at
insulin concentrations of 350 pmol/l, but was further
suppressed in the diabetic subjects at insulin concentra-
tions up to 700 U/ml. SGU was lower in the diabetic
than nondiabetic subjects at all insulin concentrations
tested, whereas glucose production only was higher in the
diabetic than in the nondiabetic subjects during the low-
est-dose insulin infusion. These data indicate that the
insulin dose-response curves for stimulation of SGU and
suppression of glucose production differ in nondiabetic
humans and are abnormal in people with type 2 diabetes.
Effects of insulin on SGU and splanchnic glucose
production in nondiabetic humans. In the presence of
hyperglycemia, SGU increased with increasing insulin
concentrations in the nondiabetic subjects. This observa-
tion is consistent with that previously reported by Myers et
al. (17) in nondiabetic dogs and by Petersen et al. (18) and
ourselves (6,7) in humans. At the lowest insulin concen-
trations tested (150 pmol/l), SGU averaged 8.5 mol 
kg1  min1, accounting for 23% of total body uptake.
However, this comparison likely underestimates the po-
tential contribution of hepatic glucose uptake to overall
carbohydrate tolerance in the postprandial setting because
portal insulin concentrations are several fold higher than
peripheral insulin concentrations following food ingestion
(i.e., when both glucose and insulin concentrations are
normally increased). Assuming a portal venous–to–periph-
eral venous insulin gradient of 2.3 to 1 (13,15), the 37
mol  kg1  min1 of total glucose uptake observed in the
presence of peripheral insulin concentrations of 150
pmol/l would be accompanied by portal venous insulin
concentrations of 350 pmol/l and SGU of 11.2 mol 
kg1  min1. Under these circumstances, the splanchnic
bed would account for 30% of insulin-stimulated glucose
uptake. These numbers are estimates of the potential
rather than the actual effects of insulin observed after
eating a carbohydrate-containing meal, because in that
situation glucose and insulin concentrations are not main-
tained at a constant level, as was done in the current
experiments, but rather are continuously changing. There-
fore, the prolonged insulin infusions may have resulted in
higher rates of SGU and extrasplanchnic glucose uptake
than would occur following a briefer increase in insulin
concentrations. On the other hand, glucose concentrations
following food ingestion are higher in the portal than
hepatic vein, likely leading to greater hepatic glucose
uptake than occurs when all glucose is given intrave-
nously, as was done in the present experiments (17).
In the presence of hyperglycemia and hyperinsulinemia,
the majority of nonhepatic glucose uptake is believed to
occur in muscle. In the present experiments, leg glucose
FIG. 6. SGU observed in nondiabetic subjects from 150 to 180 min, 210
to 240 min, and 390 to 420 min during a 7-h low-dose (150 pmol/l)
insulin infusion. The insulin, somatostatin, glucagon, and growth hor-
mone infusions started at time 0.
TABLE 1
7-h low-dose insulin infusion in nondiabetic subjects
0 min 150–180 min 270–300 min 390–420 min
Glucose (mmol/l) 5.7  0.3 9.1  0.1 9.5  0.1 9.5  0.1
Insulin (pmol/l) 37.0  6.0 194.0  24.0 199.0  20.0 196.0  26.0
C-peptide (nmol/l 0.55  0.09 0.06  0.03 0.04  0.01 0.04  0.01
Glucagon (pg/ml) 121.0  15.0 122.0  9.0 114.0  10.0 104.0  8.0
Glucose infusion rate (mol  kg1  min1) — 52  4 60  5 57  2
[3-3H]glucose specific activity (dpm/mol) — 373  28 390  33 395  30
Data are means  SE.
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extraction and uptake increased 3- and 4.8-fold, respec-
tively, as insulin was increased from 150 to 700 pmol/l.
The proportionately greater increase in LGU than leg
glucose extraction resulted from a slight but nonsignifi-
cant increase in leg blood flow with increasing insulin
concentrations. On the other hand, splanchnic glucose
extraction and SGU only increased 1.75-fold, indicating a
greater range of response to insulin in the leg than in the
liver. The true dose-response curves for these tissues are
not known because the present experiments began with
insulin concentrations in the midphysiologic range and
there was no evidence of a maximal response in either
tissue at the highest insulin concentration tested. Never-
theless, the wider range of response to insulin in the leg
than in the splanchnic bed indicates the relative contribu-
tion of each to glucose disposal; therefore, carbohydrate
tolerance will change as insulin concentrations change.
Consistent with previous experiments (1,3,6,13,14),
maximal suppression of glucose production in the nondi-
abetic subjects occurred at insulin concentrations be-
tween 150 and 350 pmol/l. In contrast, as noted above,
SGU continued to increase at insulin concentrations up to
700 pmol/l. Therefore, the mechanism by which insulin
regulates these processes must differ. The amount of
glucose released by the liver is determined by the balance
between the rate that intrahepatic free glucose is phos-
phorylated to glucose-6-phosphate by glucokinase and the
rate at which glucose-6-phosphate is dephosphorylated to
glucose by glucose-6-phosphatase. Insulin regulates flux
through the glucose-6-phosphatase pathway both directly
by altering the expression of the enzyme and indirectly by
lowering other regulators such as free fatty acid concen-
trations (18,28,37–40). On the other hand, insulin in-
creases hepatic glucose uptake by increasing the activity
of glucokinase and glycogen synthetase (18,40,41). In the
presence of hyperglycemia, insulin can also stimulate
glycogen synthetase by increasing intrahepatic glucose-6-
phosphate concentrations (24). Since glucokinase is be-
lieved (41–43) to be rate limiting for hepatic glucose
uptake, the present experiments imply that insulin concen-
trations sufficient to maximally suppress flux through
glucose-6-phosphatase are not sufficient to maximally
stimulate flux through glucokinase. Therefore the signals
regulating these pathways must differ.
Glucagon concentrations were maintained constant at
all insulin concentrations. In addition, while we did not
measure free fatty acid concentrations, previous experi-
ments (14) have shown that they are maximally sup-
pressed in nondiabetic subjects at insulin concentrations
150 pmol/l. Therefore neither likely played a role in the
modulation of glucose production and uptake under the
present experimental conditions. Insulin can increase both
the amount and activity of hepatic glucokinase, leaving
open the possibility that the 7-h insulin infusion stimulated
glucokinase synthesis (28). However, the effects of insulin
on SGU did not appear to change with time because the
rates did not differ from 180 min onward during the 7-h
0.5-mU/kg insulin infusion. This observation is consistent
with previous reports (16,17) wherein the effects of insulin
on splanchnic glucose balance reach a plateau within 90
min.
Taken together, the present data indicate that the shape
of the insulin dose-response curves for the regulation of
hepatic glucose release and uptake differ, with the former
being very sensitive to small changes in insulin and the
latter continuing to increase at insulin concentrations
spanning the physiologic range. They also indicate that in
the presence of physiologic insulin concentrations, the
splanchnic bed can account for 25–30% of total body
glucose uptake.
The effects of type 2 diabetes on the ability of insulin
to regulate SGU and splanchnic glucose production.
The present data once again demonstrate that type 2
diabetes impairs insulin-induced suppression of glucose
production and stimulation of SGU and LGU (1–3,6,7,13).
However, although glucose production was eventually
suppressed to nondiabetic rates, both SGU and LGU
remained lower than nondiabetic rates at insulin con-
centrations spanning the physiologic range. As with the
nondiabetic subjects, the relative contribution of the
splanchnic bed and muscle (as reflected by LGU) to total
body uptake in the diabetic subjects differed depending on
the prevailing insulin concentration. In the nondiabetic
subjects, leg glucose extraction was two- to threefold
greater than splanchnic glucose extraction at all insulin
concentrations examined. In contrast, splanchnic and leg
fractional glucose extraction (both 2%) were virtually
identical in the diabetic subjects at insulin concentrations
of 150 pmol/l (Figs. 4 and 5). In addition, the absolute
amount of glucose taken up in the diabetic subjects by the
splanchnic bed at those insulin concentrations (3.3 mol
 kg1  min1) exceeded that taken up by both legs (2.4
mol  kg1  min1, assuming equivalent uptake in each
leg). This emphasizes the marked degree of muscle insulin
resistance in people with type 2 diabetes as well as the
importance of hepatic glucose uptake in the regulation of
glucose tolerance in the presence of low physiologic
insulin concentrations. On the other hand, the relative
contribution of muscle and SGU changed as insulin con-
centrations increased. Leg fractional glucose extraction in
the diabetic subjects was twofold greater than splanchnic
fractional glucose extraction when insulin was increased
to 350 pmol/l (6 vs. 3%) and almost four times that of
splanchnic glucose extraction at insulin concentrations of
700 pmol/l (15 vs. 4%). This resulted in rates of SGU that
were slightly lower than those of both legs at insulin
concentrations of 350 pmol/l (5.6 vs. 6.7 mol  kg1 
min1) and substantially lower than those of both legs at
insulin concentrations of 700 pmol/l (9.2 vs. 22.4 mol 
kg1  min1). Thus, although the ability of insulin to
stimulate muscle glucose uptake is severely impaired in
diabetic subjects, as with nondiabetic subjects, the range
of response to insulin substantially exceeds that of the
liver. Nevertheless, in the presence of insulin concentra-
tions likely to be present in diabetic individuals under the
conditions of daily living, SGU is likely to make a substan-
tial contribution to total glucose uptake in people with
type 2 diabetes.
The highest insulin concentration examined in the
present experiments was 700 pmol/l. We therefore do
not know whether SGU and LGU would have eventually
reached the same maximal rates if the insulin concentra-
tions were increased to sufficiently high concentrations.
Previous studies (1,3,13,14) have shown that maximal
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rates of total body glucose disposal are lower in obese
diabetic than nondiabetic subjects, similar to those who
participated in the current experiments. Interestingly, the
increment in both LGU and total body glucose disposal
when insulin was increased from 150 to 350 pmol/l was
lower in the diabetic than in the nondiabetic subjects, but
did not differ when insulin was further increased to 700
pmol/l. This indicates that the insulin dose-response curve
for both LGU and total body disposal was steeper in the
nondiabetic than diabetic subjects at lower insulin con-
centrations but appeared to become parallel at higher
concentrations. This pattern could have occurred if the
step that was both defective and rate limiting for muscle
glucose uptake at low insulin concentrations (e.g. glucose
transport and/or phosphorylation) in the diabetic subjects
was no longer rate limiting at higher insulin concentra-
tions. In contrast, while the absolute rate of SGU was
lower in the diabetic than nondiabetic subjects, the incre-
ment in uptake with each increment in insulin did not
differ between groups. Glucokinase is believed to be rate
limiting for hepatic glucose uptake, and the amount and
activity of hepatic glucokinase has been reported (42–45)
to be lower in animal models of diabetes and in people
with diabetes. Therefore, the right-shifted (i.e. lower but
parallel) insulin dose curve for stimulation of SGU could
be explained if the amount of active glucokinase was
reduced in the diabetic subjects in the basal state with
preserved translocation and activation of glucokinase in
response to an increment in insulin. It would be of interest
in this regard if the insulin dose-response curve for the
stimulation of hepatic glucose uptake also is shifted to the
right in individuals known to have genetic defects (i.e.,
MODY2) in the activation of hepatic glucokinase (43).
In summary, the present experiments indicate that
shape of the insulin dose-response curves for suppression
of glucose production and stimulation of SGU differ in
nondiabetic subjects. Whereas a relatively small increase
in insulin results in maximal suppression of glucose pro-
duction, SGU continues to increase at insulin concentra-
tions spanning the physiologic range. Type 2 diabetes
impairs both processes, with the defect in insulin-induced
suppression of glucose production only being evident at
lower insulin concentrations. In the presence of hypergly-
cemia, insulin-induced stimulation of SGU and muscle
glucose uptake both contribute to overall glucose disposal
in both diabetic and nondiabetic subjects. However, due to
the presence of marked insulin resistance in muscle, the
relative contribution of SGU to overall glucose disposal is
greater in diabetic subjects, particularly at insulin concen-
trations likely to be present under conditions of daily
living. Finally, the right shifted but parallel insulin dose-
response curve for the stimulation of SGU observed in the
diabetic subjects suggests a defect that lowers basal rates
of uptake but does not alter the subsequent response to
insulin. However, because the subjects who participated in
the present studies were on average either overweight or
obese and were predominantly 50–70 years of age, addi-
tional studies will be required to determine whether these
conclusions also apply to people with type 2 diabetes
whose age and degree of adiposity differs. Nevertheless,
taken together, these data emphasize the importance of
SGU as a contributor to overall glucose disposal. They also
suggest that agents that enhance SGU in diabetic patients
(e.g. glucokinase activators) are likely to have favorable
effects on glucose tolerance.
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